Novo's dark forecasts have been disproved: "We're stronger in the US than we've been in many years"
Danish pharmaceutical company Novo Nordisk's largest single market business has proven – in record time – to be stronger than the firm expected.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has refuted skepticism and successfully led its US business to provide even better results than the pharmaceutical company had otherwise dared hope.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings buys Canadian life science company
For subscribers
Analyst emphasizes 2021 guidance in Genmab fiscal report
For subscribers
